Angiotensin-receptor blockade, cancer, and concerns

The Lancet Oncology

Volumn 11, Issue 9, 2010, Pages 820-821

  Julius, Stevo ^a   Kjeldsen, Sverre E ^b   Weber, Michael A ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ACCESS TO INFORMATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA BASE; DATA COLLECTION METHOD; HUMAN; HYPERTENSION; LETTER; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); META ANALYSIS (TOPIC); NEOPLASM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS;

EID: 77956139243     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70159-5     Document Type: Letter

References (3)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11:627-636.
2. Nissen SE Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol 2010, 11:605-606.
3. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.